Methods and products related to metabolic interactions in disease

• US 20050074882A1
• Filed: 07/09/2003
• Published: 04/07/2005
• Est. Priority Date: 04/17/1998
• Status: Abandoned Application

• Current Assignee: University of Vermont & State Agricultural College
• Original Assignee: University of Vermont & State Agricultural College
• Inventors: Newell, Martha Karen
• Application Number:
  US10/616,865
• Publication Number:
  US 20050074882A1
• Time in Patent Office: Days
• US Class Current: 435/455
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/57 characterised by the type of response, e.g. Th1, Th2
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 38/1825 Fibroblast growth factor [FGF]
• CPC Class Codes: A61K 38/217 IFN-gamma
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/70532 B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C07K 14/70539 MHC-molecules, e.g. HLA-molecules
• CPC Class Codes: G01N 33/5005 involving human or animal cells immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025
• CPC Class Codes: G01N 33/56977 HLA or MHC typing

Abstract

The invention involves methods of regulating cell growth and division to control disease processes by manipulating mitochondrial metabolism and the expression of cell surface immune proteins. The invention also involves related compositions and screening assays.

Claims

1-142. -142. (Cancelled)

143. A method of inducing tumor cell death, comprising administering to a subject, a therapeutically effective amount of an anti-HLA-DR antibody effective to induce tumor cell death in HLA-DR-expressing tumor cells.

144. The method of claim 143 wherein the therapeutic outcome of the subject is improved following said administration.

145. The method of treating cancer according to claim 144 wherein said cancer is selected from the group consisting of multiple myeloma, lymphoma'"'"'s including Hodgkin'"'"'s lymphomas, lymphocytic lymphomas and leukemias.

146. The method of claim 144 wherein the anti-HLA-DR antibody is administered intravenously.

147. The method of claim 144 wherein the anti-HLA-DR antibody is administered parenterally.